Aspirin Cancer Prevention: 5 Shocking New Findings From Groundbreaking Research
Aspirin cancer prevention has moved from theory to molecular science. For years, clinical data has suggested that regular aspirin use reduces the risk of colorectal cancer — but the biological mechanism behind this effect remained unknown. A recent discovery by The Hormel Institute, affiliated with the University of Minnesota, has changed that, providing the first clear explanation of how aspirin cancer prevention actually works at the cellular level.
What Makes This Aspirin Cancer Prevention Research Different
Previous research established a statistical link between aspirin use and reduced colorectal cancer risk, but could not explain the underlying process. This new study, published in the open access journal EBioMedicine, identifies a specific molecular pathway — and opens the door to new targeted prevention strategies.
The research was led by Dr. Zigang Dong, Executive Director of The Hormel Institute, and Dr. Ann M. Bode, Associate Director and co leader of the Cellular and Molecular Biology section.
5 Shocking Findings About Aspirin Cancer Prevention
Finding 1: Aspirin Normalizes a Key Cancer Promoting Protein
The study found that aspirin may exert its cancer prevention activity by normalizing the expression of epidermal growth factor receptor (EGFR) in gastrointestinal precancerous lesions. EGFR is overexpressed in approximately 80 percent of colorectal cancer cases, making it one of the most significant drivers of the disease.
Aspirin cancer prevention, in this context, works by reducing an early molecular event — EGFR overexpression — before it progresses to cancer.
Finding 2: A Previously Unknown Link Between Two Key Enzymes Was Discovered
The research revealed a previously unknown functional connection between EGFR and COX-2, an enzyme associated with pain and inflammation. Researchers found that COX-2 may drive tumor formation, at least in part, by upregulating EGFR. Aspirin, which is known to inhibit COX-2, may therefore interrupt this pathway and reduce cancer risk through this mechanism.
Finding 3: Aspirin Cancer Prevention Works in High Risk Genetic Populations
The Hormel Institute partnered with Mayo Clinic researchers to study tissue sections from patients with familial adenomatous polyposis (FAP) — a rare inherited condition that causes polyps to form in the large intestine. Without treatment, these polyps almost always become cancerous by age 40.
The study provides a molecular explanation for why aspirin cancer prevention is effective in FAP patients, a population at extremely high colorectal cancer risk.
Finding 4: EGFR May Be a Novel Target for Colorectal Cancer Prevention
Based on their findings, researchers believe EGFR represents a promising new target for colorectal cancer prevention strategies — not just for aspirin based approaches but potentially for other drug combinations as well.
Dr. Patrignani of Italy’s University of Chieti, who published a commentary alongside the study, noted that clinical studies should be performed to evaluate whether low dose aspirin combined with other antiplatelet agents could help overcome resistance to EGFR inhibitors in cancer treatment.
Finding 5: Daily Low Dose Aspirin May Protect Against Multiple Cancer Types
The accumulating data from randomized clinical trials now supports considering daily aspirin use not only for colorectal cancer prevention but potentially for other cancer types as well. Researchers note that key questions remain — including whether the protective effect is dose dependent and how aspirin interacts with other cancer pathways.
For more information on colorectal cancer prevention research, visit the National Cancer Institute and search for active prevention studies at ClinicalTrials.gov.
What Comes Next in Aspirin Cancer Prevention Research
The Hormel Institute is continuing this line of research on multiple fronts. Dr. Zigang Dong received a grant of more than $1.7 million over five years from the National Cancer Institute to continue supercomputer assisted development of agents that are more effective and less toxic in preventing and treating colorectal cancer.
Using two IBM supercomputers, Drs. Dong and Bode have already identified three small molecules that suppress colon cancer cell growth by inhibiting a key enzyme called beta catenin, which promotes tumor formation across many cancer types.
A separate study by the same team also identified the TXA2 pathway as an important factor in colorectal cancer development, suggesting that circulating TXA2 levels may serve as a biomarker for early detection.
Supporting Cancer Research Through Clinical Trials
Advances in aspirin cancer prevention and colorectal cancer research depend on robust clinical trial participation. At FOMAT Medical, we support Phase I through Phase IV studies across multiple therapeutic areas throughout the United States, including oncology research.
If you or someone you know is interested in participating in an active clinical study, explore our currently available trials.